17.97
Amylyx Pharmaceuticals Inc stock is traded at $17.97, with a volume of 1.36M.
It is down -1.64% in the last 24 hours and up +34.91% over the past month.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
See More
Previous Close:
$18.27
Open:
$18.01
24h Volume:
1.36M
Relative Volume:
1.02
Market Cap:
$2.00B
Revenue:
$-665.00K
Net Income/Loss:
$-150.11M
P/E Ratio:
-11.92
EPS:
-1.5071
Net Cash Flow:
$-124.53M
1W Performance:
-3.90%
1M Performance:
+34.91%
6M Performance:
+57.91%
1Y Performance:
+185.24%
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
Name
Amylyx Pharmaceuticals Inc
Sector
Phone
617-682-0917
Address
55 CAMBRIDGE PARKWAY, CAMBRIDGE
Compare AMLX vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
AMLX
Amylyx Pharmaceuticals Inc
|
17.97 | 2.00B | -665.00K | -150.11M | -124.53M | -1.5071 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.89 | 50.65B | 29.91B | 1.30B | 3.49B | 0.4056 |
|
HLN
Haleon Plc Adr
|
9.72 | 41.09B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.29 | 39.45B | 17.53B | 1.58B | 444.18M | 1.3457 |
|
ZTS
Zoetis Inc
|
75.42 | 30.13B | 9.51B | 2.64B | 2.14B | 6.0361 |
|
UTHR
United Therapeutics Corp
|
547.25 | 23.00B | 3.17B | 1.29B | 1.01B | 27.09 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-03-26 | Initiated | Stifel | Buy |
| Jul-10-25 | Resumed | Goldman | Buy |
| Jun-24-25 | Initiated | Guggenheim | Buy |
| Jun-17-25 | Initiated | Citigroup | Buy |
| May-30-25 | Initiated | TD Cowen | Buy |
| Apr-07-25 | Upgrade | Mizuho | Neutral → Outperform |
| Nov-18-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-23-24 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-18-24 | Downgrade | Mizuho | Buy → Neutral |
| Mar-11-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-11-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-08-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-08-24 | Downgrade | Goldman | Buy → Neutral |
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Jul-24-23 | Upgrade | Goldman | Neutral → Buy |
| Mar-31-23 | Initiated | Mizuho | Buy |
| Jan-05-23 | Initiated | BofA Securities | Buy |
| May-25-22 | Initiated | Citigroup | Buy |
| Apr-01-22 | Downgrade | Goldman | Buy → Neutral |
View All
Amylyx Pharmaceuticals Inc Stock (AMLX) Latest News
Is Amylyx Pharmaceuticals, Inc. (AMLX) Stock Ready for a Breakout Ahead of Key LUCIDITY Trial Data? - Insider Monkey
Amylyx Pharmaceuticals, Inc.(NasdaqGS: AMLX) dropped from Russell 3000E Index - marketscreener.com
Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Amylyx Pharmaceuticals, Inc.(NasdaqGS: AMLX) dropped from Russell Microcap Index - marketscreener.com
Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) dropped from Russell 3000 Value Benchmark - marketscreener.com
Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) dropped from Russell 2500 Value Benchmark - marketscreener.com
12 Best Low-Priced Pharma Stocks to Buy Right Now - Insider Monkey
Enterprise value to EBIT forward of Amylyx Pharmaceuticals, Inc. – NASDAQ:AMLX - TradingView
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gew - The National Law Review
Amylyx advancing ALS treatment in trial after early safety data is positive - ALS News Today
Enterprise value to revenue forward of Amylyx Pharmaceuticals, Inc. – NASDAQ:AMLX - TradingView
Price to sales forward of Amylyx Pharmaceuticals, Inc. – NASDAQ:AMLX - TradingView
Enterprise value to EBITDA forward of Amylyx Pharmaceuticals, Inc. – NASDAQ:AMLX - TradingView
Guggenheim Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Amylyx Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:AMLX) - TradingView
AMLX Forecast — Price Target — Prediction for 2027 - TradingView
Amylyx Pharmaceuticals stock hits 52-week high at $18.65 By Investing.com - Investing.com South Africa
AMLX Maintained by Guggenheim -- Price Target Raised to $40 - GuruFocus
Guggenheim raises Amylyx stock price target on PBH drug outlook By Investing.com - Investing.com South Africa
Guggenheim raises Amylyx stock price target on PBH drug outlook - Investing.com UK
Amylyx Pharmaceuticals stock hits 52-week high at $18.65 - Investing.com
Guggenheim Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $40 - Moomoo
H.C. Wainwright Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $34 - Moomoo
Amylyx Pharmaceuticals Inc (AMLX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026 - BioSpace
Amylyx presents early safety data for ALS drug candidate AMX0114 By Investing.com - Investing.com Nigeria
Amylyx presents early safety data for ALS drug candidate AMX0114 - Investing.com
Amylyx says ALS drug AMX0114 showed no serious safety issues - Stock Titan
Amylyx Pharmaceuticals Inc (AMLX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
AMLXAmylyx Pharmaceuticals Inc Latest SEC Filings - Finviz
Amylyx Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Firestone Karen - Moomoo
Amylyx Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director MILNE GEORGE M JR - Moomoo
Goldman Sachs Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $23 - Moomoo
Amylyx Pharmaceuticals Inc (AMLX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Amylyx Pharmaceuticals Inc (AMLX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Amylyx Pharmaceuticals Inc (AMLX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Amylyx Pharmaceuticals Inc (AMLX) Institutional Confidence - TradingKey
Amylyx Pharmaceuticals Inc (AMLX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Amylyx Pharmaceuticals Inc (AMLX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Amylyx Pharmaceuticals Inc (AMLX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Amylyx Pharmaceuticals eyes Q3 phase 3 Avexitide readout as PBH launch plans take shape - MSN
How Amylyx’s Class Action Settlement and Phase 3 Avexitide Milestone At Amylyx Pharmaceuticals (AMLX) Has Changed Its Investment Story - simplywall.st
Amylyx Pharmaceuticals Eyes Q3 Phase 3 Avexitide Readout as PBH Launch Plans Take Shape - Yahoo Finance
Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026 - BioSpace
Amylyx (NASDAQ: AMLX) director receives 24,372 stock options grant - Stock Titan
Amylyx (AMLX) director Karen Firestone receives 24,372 stock options grant - Stock Titan
Amylyx (NASDAQ: AMLX) director receives 24,372-share stock option grant - Stock Titan
Amylyx (NASDAQ: AMLX) director awarded 24,372 stock options at $14.31 strike - Stock Titan
Amylyx (AMLX) director Paul Fonteyne receives grant of 24,372 stock options - Stock Titan
Claim your share of the $6.5M Amylyx Pharmaceuticals securities class action settlement - Claim Depot
Amylyx Pharmaceuticals Inc Stock (AMLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Amylyx Pharmaceuticals Inc Stock (AMLX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Klee Justin B. | Co-Chief Executive Officer |
Mar 02 '26 |
Sale |
14.47 |
29,282 |
423,760 |
3,334,616 |
| Cohen Joshua B | Co-Chief Executive Officer |
Mar 02 '26 |
Sale |
14.48 |
29,282 |
424,120 |
3,334,683 |
| Bedrosian Camille L | Chief Medical Officer |
Mar 02 '26 |
Sale |
14.58 |
6,461 |
94,205 |
169,295 |
| FRATES JAMES M | Chief Financial Officer |
Mar 02 '26 |
Sale |
14.52 |
7,909 |
114,851 |
165,638 |
| Mazzariello Gina | Chief Legal Officer |
Mar 02 '26 |
Sale |
14.52 |
6,844 |
99,378 |
134,430 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):